| Esophageal carcinoma is one of the commonest malignant tumors of digestive system. In our country, its mortality rate is the fourth, only following lung cancer, gastric cancer, and hepatocancinoma, with severely threaten people's health. Because the morbidit of most esophageal carcinoma is latent, over-half patients are in the advanced stage and lose the opportunity of surgery or radiotherapy. Therefore, chemotherapy is becoming more and more important in the therapy of esophageal carcinoma. No matter, being the mainly therapy method of the advanced stage patients or the assistant approach of perioperative, chemotherapy is playing an important role in elongating the patient survival time and improving the life quality. Especially preoperative chemotherapy carries to a new level in comprehensive therapy of esophageal carcinoma. Based on the reasons above-mentioned, more and more researchers showed interest in this field. It includes two hotspots: 1. One is exploiting new drug and instituting the new project. 2. Another is more clarifying the exact mechanisms of chemotherapy drugs cells.Paclitaxel is a kind of floristic anti-cancer drugs coming out in recent years. There are some reports about clinical research of esophageal carcinoma therapy by Paclitaxel, however, there are little literatures about Paclitaxel 's basic research both in internal and overseas, especially no basic research reports have shown in Paclitaxel combined other drugs.At present, chemotherapy project based on cisplatin is broadly used in clinic, and its curative effect is affirmative. However, to some patients it is inefficient except for the character of esophageal carcinoma, the significant side-effects of chemotherapy and drugresistance are also important reasons. Therefore, it is important to look for more reliable and objective index to assess and select anti-cancer drugs in therapy of esophageal carcinoma.Cell cycle is a continuous course. The organism synthesis in any phases of cell cycle being blocked, the whole cycle will be halt. To explore the difference of cell cycle caused by drugs can help us to understand the mechanisms of drugs more deeply, and also can instruct clinical medication.Based on the reasons above-mentioned, in this investigation, cisplatin, 5-fluorouracil, Paclitaxel, cisplatin + 5-fluorouracil, and cisplatin + Paclitaxel were chosen, they were all frequent drugs and projects in therapy of esophageal carcinoma. Human esophageal carcinoma cell line-109 (ECa-109) is the trial object. We were to clarify them more in two aspects: cell cycle and induced apoptosis, and clarify the mechanism of chemotherapy drugs deeply, thus providing the theoretical basis for clinical medication of esophageal carcinoma.Materials and Methods:1. Human esophageal carcinoma cell line 109 was chosen as the trial material. 2. Chemotherapy drugs included 5-fluorouracil (5-Fu), cis-Dismine dichloroplatinum (DDP) and Paclitaxel (taxol). 3. MTT assay was used to examine suppressive rate of cell growth dealt with different concentration of drugs, and the appropriate concentration of flow cytometry examination was determined. 4. The development of cell cycle and apoptosis caused by different drugs management groups was examined by flow cytometry. 5.With SPSS 10.0 software package, one-way ANOVA and Chi-Square test were used to analyze all experimental data, size of the test was P<0.05.Results: 1. MTT assay showed that different concentration of DDP, 5-Fu, and Taxol single could effectively inhibit the growth of cell line Eca-109, compared all of the management groups to control group, difference of OD value had statistical meaning (P<0.05) . Chose the drug concentration that caused the inhibitory rate was 20%-30%, 50%, 70%-80%% respectively as the examined concentration of flow cytometry: DDP were 0.2 u g/ml, 3.2 u g/ml, 12.8 n g/ml; 5-Fu were 3.13 w g/ml, 50 w g/ml, 200 u g/ml; Taxol were 0.00313 u g/ml, 0.025 u g/ml, 0.2 u g/ml. The project of DDP+Taxol and DDP+5-Fu could also effectively inhibit the growth of Eca-1...
|
PDF Full Text Request